Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global life sciences company dedicated to protecting and enhancing life by providing solutions for public health threats. The company focuses on developing, manufacturing, and delivering a portfolio of medical countermeasures designed to address accidental, deliberate, and naturally occurring health emergencies. Its key products include NARCAN Nasal Spray for opioid overdose reversal, vaccines such as Vaxchora for cholera and Vivotif for typhoid fever, and critical treatments for anthrax like Anthrasil and BioThrax. Emergent also offers a smallpox vaccine, ACAM2000, and treatments for botulism and Ebola, including Ebanga. The company is actively engaged in research and development for novel therapeutics targeting emerging infectious diseases like Lassa fever, Marburg virus, and Sudan virus. Beyond its proprietary product lines, Emergent BioSolutions leverages its extensive manufacturing capabilities to provide contract development and manufacturing services to other pharmaceutical and biotechnology companies. This dual approach, combining a robust product pipeline with specialized manufacturing expertise, positions Emergent as a key partner for governments and healthcare systems seeking to bolster their preparedness and response strategies against a wide spectrum of health crises.